Vector-Based RNAi Market

Vector-based RNAi (RNA interference) offers a system of treatment and disease management to decrease the inhibition of gene translation or expression, as well as it neutralizes the targeted mRNA molecules. Vector-based RNAi plays very important in cancer treatment,cancer is the top second cause of death across the globe. As well as a new development in vector-based RNAi such as small interfering RNAs (siRNA) and microRNAs (miRNA) can escalate the vector-based RNAi market growth. The challenging situation of FDA approval affecting on a number of new drugs launch, for instance, 2015 (41 drugs), while in 2016 (19 drugs) which are very less as compared with the previous year.
Vector-Based RNAi Market contains market size and forecasts of Vector-Based RNAi in global, including the following market information:
Global Vector-Based RNAi Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Vector-Based RNAi Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Vector-Based RNAi companies in 2021 (%)
The global Vector-Based RNAi market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
siRNA Design Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Vector-Based RNAi include Merck & Co., Phio Pharmaceutical, Quark Pharmaceuticals, Thermo Fisher Scientific, Silence Therapeutics, Qiagen NV, Ionis Pharmaceutical, Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Vector-Based RNAi manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Vector-Based RNAi Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Vector-Based RNAi Market Segment Percentages, by Type, 2021 (%)
siRNA Design
siRNA Vectors
Custom siRNA Construction
Global Vector-Based RNAi Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Vector-Based RNAi Market Segment Percentages, by Application, 2021 (%)
Hospitals
Speciality Clinics
Global Vector-Based RNAi Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Vector-Based RNAi Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Vector-Based RNAi revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Vector-Based RNAi revenues share in global market, 2021 (%)
Key companies Vector-Based RNAi sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Vector-Based RNAi sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck & Co.
Phio Pharmaceutical
Quark Pharmaceuticals
Thermo Fisher Scientific
Silence Therapeutics
Qiagen NV
Ionis Pharmaceutical
Dicerna Pharmaceuticals
Arrowhead Pharmaceuticals
Arcturus Therapeutics
Alnylam Pharmaceuticals